Part B “Evidence Development” Plan Needs Defined Scope – Manufacturers

The Centers for Medicare & Medicaid Services needs to more clearly define the circumstances for applying a determination of coverage with evidence development for Medicare Part B-covered drugs, BIO and PhRMA say in comments on a draft guidance